ResMed Inc. (ASX: RMD) shares surged 5.68% in Thursday's intraday trading session following the release of its strong fiscal third-quarter results that exceeded analyst expectations.

The medical device company, which specializes in sleep apnea and respiratory care, reported a non-GAAP earnings per share (EPS) of $2.37 for the quarter ended March 31, 2025. This figure surpassed the Zacks Consensus Estimate of $2.36 per share and represented a significant improvement from $2.13 per share in the same quarter last year. ResMed's revenue for the quarter reached $1.29 billion, up 8% year-over-year and slightly above the consensus estimate of $1.28 billion.

Key highlights from ResMed's Q3 fiscal 2025 results include: - Revenue growth of 9% on a constant currency basis - Gross margin improvement of 140 basis points to 59.9% (non-GAAP) - Operating profit increase of 14% (GAAP) and 13% (non-GAAP) - Strong cash flow generation with $579 million in operating cash flow Mick Farrell, ResMed's Chairman and CEO, attributed the positive performance to "solid customer demand for our best-in-class products and software solutions." The company's focus on innovation in sleep health and breathing health solutions, coupled with its expanding digital health technologies, continues to drive growth and market leadership.

Investors responded positively to ResMed's ability to navigate challenges and deliver strong results amid a complex healthcare landscape. The company's consistent performance and strategic positioning in high-growth areas of respiratory care and digital health solutions have reinforced market confidence in its long-term prospects.